Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5823865 | 0.90 | KCNH2 (0.43) | KCNH2JAK2JAK1TYK2JAK3 | |
| SCHEMBL5450730 | 0.88 | JAK2 (0.38) | KCNH2JAK2JAK1TYK2JAK3 | |
| SCHEMBL5466639 | 0.88 | KCNH2 (0.41) | KCNH2JAK2JAK1TYK2JAK3 | |
| SCHEMBL5460508 | 0.88 | KCNH2 (0.42) | KCNH2JAK2JAK1TYK2JAK3 | |
| SCHEMBL5465186 | 0.87 | KCNH2 (0.46) | KCNH2JAK2JAK1TYK2JAK3 | |
| SCHEMBL5455732 | 0.87 | KCNH2 (0.43) | KCNH2JAK2JAK1TYK2JAK3 | |
| SCHEMBL5461882 | 0.87 | KCNH2 (0.43) | KCNH2JAK2JAK1TYK2JAK3 | |
| SCHEMBL5454102 | 0.84 | KCNH2 (0.38) | KCNH2JAK2JAK1TYK2JAK3 | |
| SCHEMBL5458199 | 0.84 | KCNH2 (0.48) | KCNH2CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL5460712 | 0.84 | KCNH2 (0.49) | KCNH2CYP3A4CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191333-A1 | Antibacterial agents | WARNER LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | claimed |
| US-20070191333-A1 | Antibacterial agents | WARNER LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191333-A1 | Antibacterial agents | WARNER LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
| EP-1687296-A1 | ANTIBACTERIAL AMINOQUINAZOLIDINEDIONE DERIVATIVES | Warner-Lambert Company LLC (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005049605-A1 | ANTIBACTERIAL AMINOQUINAZOLIDINEDIONE DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191333-A1 | Antibacterial agents | MRPL21, RPN2, FBL | KCNH2 2633/4885JAK2 4764/4885JAK1 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.